Fulcrum Therapeutics (FULC) Operating Expenses (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Operating Expenses data on file, last reported at $22.2 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 8.74% year-over-year to $22.2 million in Q1 2026; TTM through Mar 2026 was $86.6 million, a 6.4% decrease from a year earlier, with the FY2025 full-year figure at $84.8 million, down 16.81% from the prior year.
• Operating Expenses for Q1 2026 stood at $22.2 million, down from $22.7 million in the prior quarter.
• Over the last five years, Operating Expenses for FULC reached as high as $36.1 million in Q2 2022 and fell as low as $19.4 million in Q4 2024.
• Historically, Operating Expenses has averaged $26.0 million across 5 years, with a median of $27.5 million in 2024.
• Across the five-year window, Operating Expenses soared 50.09% in 2022 and plunged 32.69% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $28.7 million in 2022, then advanced by 0.72% to $28.9 million in 2023, then tumbled by 32.69% to $19.4 million in 2024, then climbed by 16.8% to $22.7 million in 2025, then fell by 2.23% to $22.2 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $22.2 million in Q1 2026, $22.7 million in Q4 2025, and $21.9 million in Q3 2025.